2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Factor Xa

Factor Xa

Fxa

Factor Xa

Related Products

PDF 0.5 MB

Factor Xa, a trypsin-like serine protease, is situated at the critical juncture between the intrinsic and extrinsic pathways, catalyzing the conversion of prothrombin to thrombin, and hence plays a pivotal role in the final common pathway of the cascade and has become an important target in the discovery and development of new anticoagulants. Factor Xa is a key protease of the coagulation pathway whose activity is known to be in part modulated by binding to factor Va and sodium ions.

Blood coagulation involves a complex cascade of enzymatic reactions, ultimately generating fibrin, the basis of all blood clots. This cascade is comprised of two arms, the intrinsic and extrinsic pathways which converge at factor Xa to form the common pathway. Factor Xa activates prothrombin to thrombin, which in turn catalyzes the conversion of fibrinogen to fibrin.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-106404
    RPR 130737
    		Inhibitor
    RPR 130737 is a selective, potent and competitive inhibitor for factor Xa with a Ki of 2.4 nM. RPR 130737 shows selectivity of more than 1000-fold over thrombin, activated protein C, plasmin, tissue-plasminogen activator and trypsin. RPR 130737 can prolong plasma activated partial thromboplastin time and prothrombin time. RPR 130737 shows no effect on platelet aggregation. RPR 130737 can be used for the research of cardiovascular disease, such as thrombosis.
    RPR 130737
  • HY-10782
    KFA-1982
    		Inhibitor
    KFA-1982 is a potent, selective and orally active factor Xa inhibitor. KFA-1982 can be used for the research of cardiovascular disease, such as thrombosis.
    KFA-1982
  • HY-19373
    RWJ-445167
    		Inhibitor
    RWJ-445167 (3DP-10017) is a dual inhibitor of thrombin and factor Xa with Ki of 4.0 nM and 230 nM, respectively, exhibiting potent antithrombotic activity.
    RWJ-445167
  • HY-10281
    YM-60828 methanesulfonate
    		Inhibitor
    YM-60828 methanesulfonate is an orally active, selective and competitive factor Xa inhibitor with a Ki of 1.3 nM and an IC50 of 2.3 nM. YM-60828 methanesulfonate inhibits thrombus formation and platelet aggregation. YM-60828 methanesulfonate can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders.
    YM-60828 methanesulfonate
  • HY-17682
    RPR-208707
    RPR-208707 is a selective factor Xa inhibitor with a Ki of 18 nM. RPR-208707 can be used for research of thrombosis-related diseases.
    RPR-208707
  • HY-P991994
    REGN9533
    		Inhibitor
    REGN9533 is a human-derived monoclonal antibody against FXII/FXIIa with high affinity for FXII, FXIIa and β-FXIIa. REGN9533 selectively inhibits the intrinsic coagulation pathway and FXIIa-driven plasma kallikrein activity. REGN9533 is applicable to FXIIa-related diseases such as thrombosis and hereditary angioedema.
    REGN9533
  • HY-182420
    DJT06001
    		Inhibitor
    DJT06001 is an orally active, highly selective Factor Xa inhibitor. DJT06001 shows inhibition with Ki of 0.99 nM, IC50 of 2.53 nM in prothrombinase complex and 3.33 nM in human plasma. DJT06001 dose-dependently prolongs PT and APTT, inhibits thrombus formation in vivo. DJT06001 can be used for the research of thromboembolic diseases.
    DJT06001
  • HY-P991993
    AB054
    		Inhibitor
    AB054 is a humanized monoclonal antibody targeting factor XII (FXII). AB054 inhibits FXII activation and FXIIa activity through specific binding to the catalytic domain of FXII, and exerts antithrombotic effects in a concentration-dependent manner. AB054 can be used in studies related to thrombosis.
    AB054
  • HY-18660A
    Ciraparantag TFA
    		Inhibitor
    Ciraparantag (PER977) TFA is a thrombin and factor Xa inhibitor. Ciraparantag TFA is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban.
    Ciraparantag TFA
  • HY-P10860
    cMCoFx1
    		Inhibitor
    cMCoFx1 is a potent and selective FXIIa cyclic peptide inhibitor. cMCoFx1 has high binding affinity (KD: 900 pM) and inhibitory activity (Ki: 370 pM) for FXIIa. cMCoFx1 can effectively inhibit endogenous clotting pathways, and cMCoFx1 is stable in serum and non-cytotoxic.
    cMCoFx1
  • HY-P3009B
    Porcine Factor Xa
    Porcine Factor Xa is prepared by activating purified Porcine Factor X with Russells' Viper Venom, after which the Russells' Viper Venom is removed.
    Porcine Factor Xa
  • HY-132587C
    Fitusiran sodium scrambled negative control
    Fitusiran sodium scrambled negative control is the sequence scrambled negative control of Fitusiran sodium. Fitusiran (ALN-AT3SC) sodium is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran sodium enhances thrombin activity and increases Thrombin generation, thereby restoring hemostatic function. Fitusiran sodium can be used in hemophilia-related research.
    Fitusiran sodium scrambled negative control
  • HY-10762
    FXa-IN-3
    		Inhibitor
    FXa-IN-3 (compound 1a) is a potent coagulation factor Xa (FXa) inhibitor with a Ki of 43 nM. FXa-IN-3 can be used in the research of thromboembolic diseases.
    FXa-IN-3
  • HY-107966
    Heparin calcium (MW 15000-19000)
    		Inhibitor
    Heparin calcium (MW 15000-19000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin.
    Heparin calcium (MW 15000-19000)
  • HY-N13960
    Bacithrocin D
    		Inhibitor
    Bacithrocin D (Thiolstatin D) inhibits multiple proteases and can prolong the clotting time. Bacithrocin D has IC50 values of 124, 9, 0.85, and 0.01 μM for thrombin, factor Xa, trypsin, and papain, respectively.
    Bacithrocin D
  • HY-10264D
    (1R,2R,4R)-Edoxaban
    		Inhibitor
    (1R,2R,4R)-Edoxaban is an oxalamide derivative. (1R,2R,4R)-Edoxaban is an activated coagulation factor X (Factor Xa) inhibitor. (1R,2R,4R)-Edoxaban can be used in the study of thrombosis.
    (1R,2R,4R)-Edoxaban
  • HY-10278
    Razaxaban
    		Inhibitor
    Razaxaban (DPC 906; BMS 561389) is a bioavtive small molecular compound.
    Razaxaban
  • HY-10279
    YM-60828 hydrochloride
    		Inhibitor
    YM-60828 hydrochloride is an orally active, selective and competitive factor Xa inhibitor with a Ki of 1.3 nM and an IC50 of 2.3 nM. YM-60828 hydrochloride inhibits thrombus formation and platelet aggregation. YM-60828 hydrochloride can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders.
    YM-60828 hydrochloride
  • HY-I0454
    Rivaroxaban EP Impurity I
    		Control 99.72%
    Rivaroxaban EP Impurity I is an impurity of Rivaroxaban (HY-50903). Rivaroxaban EP Impurity I can be used to ensure the purity of Rivaroxaban. Rivaroxaban is a highly potent, selective and direct Factor Xa (FXa) inhibitor.
    Rivaroxaban EP Impurity I
  • HY-N13950
    Bacithrocin A
    		Inhibitor
    Bacithrocin A is a thrombin inhibitor that inhibits thrombin, factor Xa, trypsin and Papain with IC50s of 48 μM, 13 μM, 0.65 μM, and 0.02 μM, respectively.
    Bacithrocin A
Cat. No. Product Name / Synonyms Application Reactivity